A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)

被引：5
|
作者：
Lenz, Heinz-Josef
Kasi, Anup
Mendelsohn, Lawrence
Cannon, Timothy Lewis
Starr, Jason S.
Hubbard, Joleen M.
Bekaii-Saab, Tanios S.
Ridinger, Maya
Samuelsz, Errin
Ruffner, Katherine L.
Erlander, Mark G.
Ahn, Daniel H.
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[2] Univ Kansas, Ctr Canc, Westwood, KS USA
[3] Little Rock Hem Onc Assoc, Little Rock, AR USA
[4] Inova Schar Canc Inst, Fairfax, VA USA
[5] Univ Florida, Hlth Canc Ctr, Jacksonville, FL USA
[6] Mayo Clin, Rochester, MN USA
[7] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[8] Cardiff Oncol, San Diego, CA USA
[9] Mayo Clin, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results
    Hendifar, A.
    Gong, J.
    Spigel, D. R.
    Basu-Mallick, A.
    Espinosa, A.
    Misleh, J. G.
    Richards, D.
    Boles, J.
    Fakih, M.
    Paulson, A. S.
    Chung, K.
    Cohn, A.
    Gupta, M.
    Johnson, K.
    Bechar, N.
    Hoffman, K. A.
    Spector, S.
    Szarek, M.
    Wasserman, R.
    Rosen, L. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S467 - S467
  • [22] Current practices in 1st-(1L), 2nd-(2L), and 3rd-line (3L) treatment for metastatic colorectal cancer (mCRC).
    Thompson, Stephen F.
    Iqbal, Sheikh Usman
    Naoshy, Sarah
    Ng, Daniel B.
    Andria, Michael L.
    Sherman, Steven A.
    Malangone, Elisabetta
    Stern, Lee
    Gorritz-Kindu, Magdaliz
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).
    Ychou, M.
    Bouche, O.
    Thezenas, S.
    Francois, E.
    Adenis, A.
    Bennouna, J.
    Taieb, J.
    Desseigne, F.
    Seitz, J.
    Conroy, T.
    Galais, M.
    Crapez, E.
    Poujol, S.
    Bibeau, F.
    Laurent-Puig, P.
    Samalin, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI plus /-bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
    O'Neil, Bert H.
    Hubbard, Joleen Marie
    Starodub, Alexander
    Jonker, Derek J.
    Edenfield, William Jeffery
    El-Rayes, Bassel F.
    Halfdanarson, Thorvardur Ragnar
    Ramanathan, Ramesh K.
    Pitot, Henry C.
    Britten, Carolyn D.
    Adesunloye, Bamidele
    Grothey, Axel
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] FOLFIRI vs FOLFOX in the general practice for metastatic colorectal carcinoma (MCRC) - Impact of 1st-line or 2nd-line treatment.
    Melosky, B
    Lohrisch, C
    Kollmannsberger, C
    Gill, S
    Kennecke, H
    Bernstein, V
    Fitzgerald, C
    Yun, J
    Shah, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 290S - 290S
  • [26] Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
    Zeidan, Amer M.
    Schiller, Gary J.
    Lin, Tara L.
    Becker, Pamela S.
    Patel, Prapti A.
    Wang, Eunice S.
    Spira, Alexander I.
    Tsai, Michaela L.
    Ridinger, Maya
    Croucher, Peter J.
    Erlander, Mark
    Silberman, Sandra L.
    BLOOD, 2019, 134
  • [27] A phase 1b/2 trial of dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC.
    Fitzgerald, Bailey Gleason
    Marron, Thomas Urban
    Hall, Nicole
    O'Grady, Daniel
    LaMarche, Nelson
    Hennequin, Clotilde
    Hegde, Samarth
    Maier, Barbara
    Le Berichel, Jessica
    Chadda, Udit
    Beasley, Mary Beth
    Yankelevitz, David F.
    Gomez, Jorge E.
    Doroshow, Deborah Blythe
    Veluswamy, Rajwanth
    Rohs, Nicholas Cole
    Rolfo, Christian Diego
    Hirsch, Fred R.
    Merad, Miriam
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)
    Samalin, E.
    Bouche, O.
    Thezenas, S.
    Francois, E.
    Adenis, A.
    Bennouna, J.
    Taieb, J.
    Desseigne, F.
    Laurent-Puig, P.
    Ychou, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S418 - S418
  • [29] Phase 1b trial of the MNK1/2 inhibitor tomivosertib combined with paclitaxel in patients with metastatic breast cancer.
    Ferrario, Cristiano
    Mackey, John
    Gelmon, Karen
    Sorensen, Poul H. B.
    Oo, Htoo Zarni
    Morin, Gregg B.
    del Rincon, Sonia
    Amiri, Mehdi
    Patel, Premal
    Smith, Harvey W.
    Sonenberg, Nahum
    Pollak, Michael N.
    CANCER RESEARCH, 2022, 82 (12)
  • [30] SPIRITT (STUDY 20060141): A RANDOMISED PHASE 2 STUDY OF FOLFIRI WITH EITHER PANITUMUMAB (pmab) OR BEVACIZUMAB (bev) AS 2ND-LINE TREATMENT (tx) IN PATIENTS (pts) WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (mCRC)
    Hecht, J. R.
    Cohn, A.
    Dakhil, S.
    Saleh, M.
    Cline-Burkhardt, M.
    Piperdi, B.
    Tian, Y.
    Go, W.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 56 - 56
12345